<DOC>
	<DOCNO>NCT00013897</DOCNO>
	<brief_summary>The purpose study compare effectiveness treatment BMS-232632 efavirenz ( EFV ) use zidovudine ( ZDV ) lamivudine ( 3TC ) .</brief_summary>
	<brief_title>A Comparison BMS-232632 With Efavirenz , Each Combination With Zidovudine-Lamivudine</brief_title>
	<detailed_description>This multinational , 2-arm study . Patients 1 arm receive BMS-232632 plus EFV placebo capsule . Patients arm receive EFV plus BMS-232632 placebo . Both arm also receive fix dose ZDV-3TC .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Have viral load 2,000 copies/ml CD4 cell count 100 cells/mm3 ( 75 cells/mm3 prior history AIDSdefining diagnosis ) within 2 week randomization . Are least 16 year old . Have sign consent parent guardian 18 year age . Are willing use effective barrier method birth control . Are available followup least 52 week . Exclusion Criteria Patients eligible study : Have antiHIV treatment within 30 day screen . Have recently diagnose HIVrelated infection . Have medical condition require treatment enrollment . Have recently become HIV infected . Have acute hepatitis within 30 day study entry . Certain patient chronic hepatitis eligible . Expect need take drug myelosuppressive , neurotoxic , pancreatotoxic , hepatotoxic , cytotoxic potential within 3 month study . Expect need methadone , ribavirin/interferons , neurotoxic drug drug affect CYP3A4 . Abuse alcohol drug . Have severe diarrhea within 30 day study entry . Are pregnant breastfeeding . Have history hemophilia . Have history bilateral peripheral neuropathy . Can take medicine mouth . Have condition doctor think would interfere study .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Placebos</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>BMS 232632</keyword>
	<keyword>efavirenz</keyword>
</DOC>